{"version":"1.0","provider_name":"ExCellThera","provider_url":"https:\/\/excellthera.com\/fr\/","author_name":"pfs","author_url":"https:\/\/excellthera.com\/fr\/author\/pfs\/","title":"ExCellThera annonce le d\u00e9p\u00f4t d\u2019un DMF pour UM171 - ExCellThera","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1KR57JU7Kb\"><a href=\"https:\/\/excellthera.com\/fr\/news\/excellthera-annonce-le-depot-dun-dmf-pour-um171\/\">ExCellThera annonce le d\u00e9p\u00f4t d\u2019un DMF pour UM171<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/excellthera.com\/fr\/news\/excellthera-annonce-le-depot-dun-dmf-pour-um171\/embed\/#?secret=1KR57JU7Kb\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0ExCellThera annonce le d\u00e9p\u00f4t d\u2019un DMF pour UM171\u00a0\u00bb &#8212; ExCellThera\" data-secret=\"1KR57JU7Kb\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/excellthera.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"MONTR\u00c9AL, le 17 juin 2022 \u2013 ExCellThera Inc. (ExCellThera), une soci\u00e9t\u00e9 d\u2019expansion et d\u2019ing\u00e9nierie cellulaire au stade clinique qui fournit des mol\u00e9cules et des solutions de bioing\u00e9nierie pour l\u2019expansion et l\u2019ing\u00e9nierie de diverses lign\u00e9es cellulaires en vue de leur utilisation dans des th\u00e9rapies cellulaires et g\u00e9niques de prochaine g\u00e9n\u00e9ration, a annonc\u00e9 aujourd\u2019hui qu\u2019elle a soumis une fiche ma\u00eetresse de m\u00e9dicament (Drug Master File ou DMF) de type II aupr\u00e8s de la Food and Drug Administration (FDA) des \u00c9tats-Unis pour UM171. Cette derni\u00e8re s\u2019agit d\u2019une mol\u00e9cule exclusive \u00e9tudi\u00e9e pour l\u2019expansion et le rajeunissement des cellules souches h\u00e9matopo\u00ef\u00e9tiques.","thumbnail_url":"https:\/\/excellthera.com\/wp-content\/uploads\/2023\/10\/ExcellThera-OG.jpg","thumbnail_width":1200,"thumbnail_height":630}